790 related articles for article (PubMed ID: 29985747)
1. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Aggarwal R; Huang J; Alumkal JJ; Zhang L; Feng FY; Thomas GV; Weinstein AS; Friedl V; Zhang C; Witte ON; Lloyd P; Gleave M; Evans CP; Youngren J; Beer TM; Rettig M; Wong CK; True L; Foye A; Playdle D; Ryan CJ; Lara P; Chi KN; Uzunangelov V; Sokolov A; Newton Y; Beltran H; Demichelis F; Rubin MA; Stuart JM; Small EJ
J Clin Oncol; 2018 Aug; 36(24):2492-2503. PubMed ID: 29985747
[TBL] [Abstract][Full Text] [Related]
2. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
Aggarwal RR; Quigley DA; Huang J; Zhang L; Beer TM; Rettig MB; Reiter RE; Gleave ME; Thomas GV; Foye A; Playdle D; Lloyd P; Chi KN; Evans CP; Lara PN; Feng FY; Alumkal JJ; Small EJ
Mol Cancer Res; 2019 Jun; 17(6):1235-1240. PubMed ID: 30918106
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
Kwon DH; Zhang L; Quigley DA; Foye A; Chen WS; Wong CK; Feng FY; Bailey A; Huang J; Stuart JM; Friedl V; Weinstein AS; Beer TM; Alumkal JJ; Rettig M; Gleave M; Lara PN; Thomas GV; Li P; Lui A; Small EJ; Aggarwal RR
Urol Oncol; 2020 Dec; 38(12):931.e9-931.e16. PubMed ID: 32624423
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
Aggarwal R; Romero GR; Friedl V; Weinstein A; Foye A; Huang J; Feng F; Stuart JM; Small EJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):81-87. PubMed ID: 32286548
[TBL] [Abstract][Full Text] [Related]
5. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
7. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
[TBL] [Abstract][Full Text] [Related]
11.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
12. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival.
Vlachostergios PJ; Karathanasis A; Tzortzis V
Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052475
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
Sowalsky AG; Ye H; Bhasin M; Van Allen EM; Loda M; Lis RT; Montaser-Kouhsari L; Calagua C; Ma F; Russo JW; Schaefer RJ; Voznesensky OS; Zhang Z; Bubley GJ; Montgomery B; Mostaghel EA; Nelson PS; Taplin ME; Balk SP
Cancer Res; 2018 Aug; 78(16):4716-4730. PubMed ID: 29921690
[TBL] [Abstract][Full Text] [Related]
15. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
[TBL] [Abstract][Full Text] [Related]
17. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
[TBL] [Abstract][Full Text] [Related]
18. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
[TBL] [Abstract][Full Text] [Related]
19. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
[TBL] [Abstract][Full Text] [Related]
20. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
